Trial Profile
Second-line Therapy With Nal-IRI After Failure Gemcitabine/Nab-paclitaxel in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms PREDICT
- 24 Oct 2023 Results (n=151) demonstrating predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma presented at the 48th European Society for Medical Oncology Congress
- 21 Jan 2023 Results assessing comprehensive evaluation of prior treatment characteristics, potential predictive factors, and quality of life presented at the 2023 Gastrointestinal Cancers Symposium
- 05 Oct 2022 Planned End Date changed from 30 Jun 2023 to 30 May 2023.